Early Virologic Failure and Rescue Therapy of Tenofovir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: TONUS Study

REFERENCES

• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, Miller R, PiIon T. Perspec-tives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative impor-tance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808–816.
   PubMed Web of Science ®Google Scholar
• SDHHS guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http:// www.hivatis.org. Accessed February 4,2002.
   Google Scholar
• Landman R, Schiemann R, Thiam S, et al. Once a day highly active antiretroviral therapy in treatment-naive HIV-1-infected adult in Senegal. AIDS. 2003;17:1017–1022.
   PubMed Web of Science ®Google Scholar
• Molina JM, Ferchal F, Rancinan C, et al. Once-daily combi-nation therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected pa-tients. J Infect Dis. 2000;182:599–602.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8(4):339–346.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2)1 91–201.
   Web of Science ®Google Scholar
• Moyle GJ. Protease inhibitor-sparing regimens: new evi-dence strengthens position. J Acquir Immune Defic Syndr (US). 2003;33\(suppl 1):S17–25.
   PubMed Web of Science ®Google Scholar
• Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods. 2001;94:45–54.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[I-2-(phosphonomethoxy) propyl] adenine (PMPA) in dogs. Antimicrob Agents Chemother. 1998; 42(3):687–690.
   PubMed Web of Science ®Google Scholar
• Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral ad-ministration of escalating single doses in human immuno-deficiency virus type 1-infected adults. Antimicrob Agents Chemother. 1999;43(3):603–608.
   PubMed Web of Science ®Google Scholar
• Harker AJ, Evans GL, Hawley AE, Morris DM. High-perfor-mance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum. J Chromatogr B Biomed App/. 1994;657(1):227–232.
   PubMed Web of Science ®Google Scholar
• Flaherty JF, Kearney BP, Wolf JJ, Sayre JR, Coakley D. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires, Argentina. Abstract 336.
   Google Scholar
• Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40(9):695–700.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleo-side regimens versus efavirenz-containing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–1861.
   PubMed Web of Science ®Google Scholar
• Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABACAVIR), lamivudine (3TC) and tenofovir DF (TDF) in treatment I HIV-infected patients. In: Program and ab-stracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment Paris; July 2003; France. Abstract 43.
   Google Scholar
• Gallant JE, Rodriguez A, Weinberg W, et al. Early virologic nonresponse to tenofovir + abacavir and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921–1930.
   PubMed Web of Science ®Google Scholar
• Jemsek J, Hutcherson P, Harper E. Poor virologic re-sponses and early emergence of resistance in treatment of naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections; Febru-ary 8–11, 2004; San Francisco. Abstract 51.
   Google Scholar
• Van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987–999.
   PubMed Web of Science ®Google Scholar
• Gerstoff J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of triple nucleoside regimen abacavir, stavudine and didanosine. AIDS. 2003; 17:2045–2052.
   PubMed Web of Science ®Google Scholar
• Ray A, Vela JE, Olson L, Eisenberg G, Fridland A. Lack of negative interaction between tenofovir and abacavir in hu-man cells. In: Program and abstracts of the 5th Interna-tional Workshop on Clinical Pharmacology of HIV Therapy; April 2004; Rome. Abstract 2.3.
   Google Scholar
• Hawkins T, Veikley W, St. Claire R, Hey A, Guyer B, Kearney BP. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regi-mens. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 2004; Rome. Abstract 2.4.
   Google Scholar
• Gazzard B, DeJesus E, Cahn P, et al. Abacavir (ABC) once daily (oad) plus lamivudine (3TC) oad in combination with efavirenz (EFV) oad is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naive adults with HIV-1 infection (ZODIAC Study: CAN 30021). In: Program and abstracts of the 43rd Interscience Conference on Anti-microbial Agents and Chemotherapy; September 2003; Chicago. Abstract H–1722a.
   Google Scholar
• Tremblay CL, Giguel F, Dong H, Chou TC, Hirsch MS. In vitro antiviral interactions among tenofovir, abacavir, didanosine and lamivudine [abstract 41]. Antiviral Ther. 2004;9:547.
   Web of Science ®Google Scholar
• Kuritzkes DR. Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen [editorial]. J Infect Dis. 2005;192:1867–1868.
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, Dejesus E, et al. C0L40263: resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral naive subjects. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic In-fections; February 8–11, 2004; San Francisco. Abstract 53.
   Google Scholar